OverviewSuggest Edit

Exact Sciences is a cancer screening and diagnostics company. It develops Cologuard, a patient-friendly non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also offers the Oncotype IQ genomic intelligence platform that is comprised of Oncotype DX gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; and Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced-stage prostate cancer.

TypePublic
Founded1995
HQMadison, WI, US
Websiteexactsciences.com
Employee Ratings4.1
Overall CultureC

Latest Updates

Employees (est.) (Dec 2020)4,833(+18%)
Job Openings559
Revenue (FY, 2020)$1.5 B(+71%)
Share Price (Sept 2021)$104.7(+8%)
Cybersecurity ratingCMore

Key People/Management at EXACT Sciences

Kevin Conroy

Kevin Conroy

Chief Executive Officer, President, and Chairman of the Board
Graham Lidgard

Graham Lidgard

Chief Science Officer, Emeritus
Matt Franklin

Matt Franklin

General Manager, Precision Oncology
Jeff Elliott

Jeff Elliott

Executive Vice President, Chief Financial Officer and Chief Operating Officer
Torsten Hoof

Torsten Hoof

General Manager, International
Jake Orville

Jake Orville

General Manager, Pipeline
Show more

EXACT Sciences Office Locations

EXACT Sciences has offices in Madison, Paris, Köln, Tokyo and in 1 other location
Madison, WI, US (HQ)
5505 Endeavor Lane
Paris, FR
7 Rue Léo Delibes
Köln, DE
Erna-Scheffler-St.
Tokyo, JP
1-5-1 Marunouchi, Chiyoda-ku
London, GB
Suite 1 The Concourse Waterloo Station
Show all (5)

EXACT Sciences Financials and Metrics

EXACT Sciences Revenue

Embed Graph
View revenue for all periods
EXACT Sciences's revenue was reported to be $1.49 b in FY, 2020 which is a 70.2% increase from the previous period.
USD

Revenue (Q1, 2021)

402.1m

Gross profit (Q1, 2021)

292.1m

Gross profit margin (Q1, 2021), %

72.6%

Net income (Q1, 2021)

(31.2m)

EBIT (Q1, 2021)

(300.5m)

Market capitalization (15-Sept-2021)

18.0b

Closing stock price (15-Sept-2021)

104.7

Cash (31-Mar-2021)

1.1b

EV

19.2b
EXACT Sciences's current market capitalization is $18 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

454.5m876.3m1.5b

Revenue growth, %

71%93%70%

Cost of goods sold

118.0m216.7m354.3m

Gross profit

336.5m659.6m1.1b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

162.0m199.9m218.8m347.8m268.9m408.4m402.1m

Cost of goods sold

43.3m51.6m52.8m81.6m77.9m95.1m110.0m

Gross profit

118.8m148.3m166.0m266.2m191.0m313.3m292.1m

Gross profit Margin, %

73%74%76%77%71%77%73%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

160.4m177.3m1.5b

Accounts Receivable

44.2m130.7m233.2m

Prepaid Expenses

20.5m40.9m33.2m

Inventories

39.1m61.7m92.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

285.2m205.1m1.0b701.1m703.9m806.7m1.1b

Accounts Receivable

56.1m63.9m82.2m140.0m163.6m206.6m256.1m

Prepaid Expenses

24.1m23.7m23.6m43.7m36.4m36.6m52.2m

Inventories

44.3m47.8m53.7m69.4m82.2m80.4m89.0m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(175.1m)(84.0m)(848.5m)

Depreciation and Amortization

23.1m50.2m163.4m

Inventories

(12.7m)(19.0m)(30.3m)

Accounts Payable

11.3m3.5m55.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(83.1m)(121.5m)(161.9m)(105.7m)(191.8m)(411.7m)(31.2m)

Depreciation and Amortization

7.1m15.0m24.2m39.3m80.4m123.5m43.7m

Inventories

(5.1m)(8.6m)(14.5m)(7.5m)(20.3m)(18.5m)3.2m

Accounts Payable

(10.6m)(8.2m)(9.0m)(18.3m)(47.6m)(7.6m)(15.9m)
USDFY, 2018

EV/EBIT

-52 x

EV/CFO

-119.6 x

Revenue/Employee

229.9k

Debt/Equity

1 x

Debt/Assets

0.5 x

Financial Leverage

2.2 x

P/E Ratio

(44.1)
Show all financial metrics

EXACT Sciences Operating Metrics

FY, 2018FY, 2019FY, 2020

Patents (US)

43110130

Patent Applications (US)

42

Patents (Foreign)

87595733

Patent Applications (Foreign)

67
Show all operating metrics

EXACT Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Ashion AnalyticsFebruary 17, 2021
Thrive Earlier Detection CorporationJanuary 04, 2021$2.15 b
Base Genomics LimitedOctober 26, 2020$416.5 m
Paradigm Diagnostics, Inc.March 03, 2020
Viomics, Inc.March 03, 2020
Biomatrica, Inc.October 31, 2018
Armune BioScienceFebruary 04, 2018
Sampleminded, Inc.August 01, 2017
Exact Sciences Development Company, LLC
Exact Sciences Laboratories LLC
Show more

EXACT Sciences Revenue Breakdown

Embed Graph

EXACT Sciences revenue breakdown by business segment: 54.7% from Screening, 29.5% from Precision Oncology and 15.8% from COVID-19 Testing

EXACT Sciences revenue breakdown by geographic segment: 94.8% from United States and 5.2% from Outside of United States

Human Capital Metrics

Embed Graph
Show all human capital metrics

EXACT Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

EXACT Sciences Online and Social Media Presence

Embed Graph

EXACT Sciences Company Culture

  • Overall Culture

    C

    67/100

  • CEO Rating

    A+

    79/100

  • Compensation

    B

    75/100

  • Diversity

    C

    66/100

Learn more on Comparably

EXACT Sciences News and Updates

Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

MADISON, Wis., Sept. 14, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a cooperative group founded by...

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score速 Program in Japan

MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurrence Score速 Program. The test helps guide chemotherapy treatment recommendations and...

Exact Sciences Said to Approach Invitae About Merger

Exact Sciences Said to Approach Invitae About Merger

Exact Sciences schedules second quarter 2021 earnings call

MADISON, Wis., July 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its second quarter 2021 financial results after the close of the U.S. financial markets on July 28, 2021. Following the release, company management will host a...

Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160

Up around 2.5x from its low in March 2020, at the current price of $126 per share, we believe EXACT Sciences Corporation stock has further upside potential. EXAS, a molecular diagnostics company, has seen its stock rise from $51 to $126 off its March 2020 low, much more than the S&P which increa…

Exact Sciences To Participate In June Investor Conferences

Exact Sciences announced that company management will participate in the following virtual conferences and invited investors to participate by webcast
Show more

EXACT Sciences Blogs

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

Improved quality of care and significant cost savings using the test to guide adjuvant chemotherapy treatment Analysis based on first results from the independent RxPONDER study which identified the majority of women with one to three positive nodes who receive no benefit from chemo…

New NCCN Breast Cancer Guidelines Recognize Oncotype DX Breast Recurrence Score® Test

Oncotype DX® Test Recognized as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

JAMIE FOXX, STAND UP TO CANCER AND EXACT SCIENCES LAUNCH PSA TO INCREASE AWARENESS OF COLORECTAL CANCER

Call to action focuses on colorectal cancer screening, early detection and prevention

The Truth About Cancer: Debunking Five Myths about the Big C

Cancer impacts all of us, yet it can be difficult to stay up to date on the latest in cancer screening and treatment guidance. Exact Sciences has teamed up with Katie Couric’s Wake-Up Call to debunk some of the most common cancer myths. Read an excerpt below.

$10 MILLION GRANT FROM EXACT SCIENCES TO SUPPORT STAND UP TO CANCER INITIATIVE TO IMPROVE COLORECTAL CANCER SCREENING AND PREVENTION

New grant will fund colorectal cancer prevention research and public awareness efforts to increase screenings, with a focus on medically underserved communities
Show more

EXACT Sciences Frequently Asked Questions

  • When was EXACT Sciences founded?

    EXACT Sciences was founded in 1995.

  • Who are EXACT Sciences key executives?

    EXACT Sciences's key executives are Kevin Conroy, Graham Lidgard and Matt Franklin.

  • How many employees does EXACT Sciences have?

    EXACT Sciences has 4,833 employees.

  • What is EXACT Sciences revenue?

    Latest EXACT Sciences annual revenue is $1.5 b.

  • What is EXACT Sciences revenue per employee?

    Latest EXACT Sciences revenue per employee is $308.6 k.

  • Who are EXACT Sciences competitors?

    Competitors of EXACT Sciences include Geneoscopy, Diatech Pharmacogenetics and Biotheranostics.

  • Where is EXACT Sciences headquarters?

    EXACT Sciences headquarters is located at 5505 Endeavor Lane, Madison.

  • Where are EXACT Sciences offices?

    EXACT Sciences has offices in Madison, Paris, Köln, Tokyo and in 1 other location.

  • How many offices does EXACT Sciences have?

    EXACT Sciences has 5 offices.